Insider Trading Alert - CBG, RPTP And ATEC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, May 22, 2015, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,297.00 to $237,892,500.00.

Highlighted Stocks Traded by Insiders:

CBRE Group (CBG) - FREE Research Report

Frese Calvin W Jr, who is CEO, Americas at CBRE Group, sold 2,661 shares at $39.00 on May 22, 2015. Following this transaction, the CEO, Americas owned 355,821 shares meaning that the stake was reduced by 0.74% with the 2,661-share transaction.

The shares most recently traded at $38.05, down $0.95, or 2.5% since the insider transaction. Historical insider transactions for CBRE Group go as follows:

  • 4-Week # shares sold: 74,876
  • 12-Week # shares sold: 74,876
  • 24-Week # shares sold: 236,988

The average volume for CBRE Group has been 1.6 million shares per day over the past 30 days. CBRE Group has a market cap of $12.7 billion and is part of the financial sector and real estate industry. Shares are up 11.8% year-to-date as of the close of trading on Friday.

CBRE Group, Inc. operates as a commercial real estate services and investment company worldwide. The company operates through Americas; Europe, Middle East and Africa; Asia Pacific; Global Investment Management; and Development Services segments. The company has a P/E ratio of 25.0. Currently, there are 4 analysts who rate CBRE Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CBG - FREE

TheStreet Quant Ratings rates CBRE Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, revenue growth, notable return on equity and good cash flow from operations. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full CBRE Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Raptor Pharmaceutical (RPTP) - FREE Research Report

Daley Thomas E, who is Chief Business Officer at Raptor Pharmaceutical, sold 10,000 shares at $12.00 on May 22, 2015. Following this transaction, the Chief Business Officer owned 64,719 shares meaning that the stake was reduced by 13.38% with the 10,000-share transaction.

The shares most recently traded at $11.70, down $0.30, or 2.56% since the insider transaction. Historical insider transactions for Raptor Pharmaceutical go as follows:

  • 4-Week # shares bought: 16,100
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 16,100
  • 12-Week # shares sold: 35,000
  • 24-Week # shares bought: 16,100
  • 24-Week # shares sold: 35,000

The average volume for Raptor Pharmaceutical has been 1.4 million shares per day over the past 30 days. Raptor Pharmaceutical has a market cap of $952.1 million and is part of the health care sector and drugs industry. Shares are up 12.45% year-to-date as of the close of trading on Friday.

Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. Currently, there are 3 analysts who rate Raptor Pharmaceutical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on RPTP - FREE

TheStreet Quant Ratings rates Raptor Pharmaceutical as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally high debt management risk. Get the full Raptor Pharmaceutical Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alphatec Holdings (ATEC) - FREE Research Report

Asai Mitsuo, who is President, Alphatec Pacific at Alphatec Holdings, bought 10,000 shares at $1.39 on May 22, 2015. Following this transaction, the President, Alphatec Pacific owned 236,610 shares meaning that the stake was boosted by 4.41% with the 10,000-share transaction.

The shares most recently traded at $1.37, down $0.02, or 1.46% since the insider transaction. Historical insider transactions for Alphatec Holdings go as follows:

  • 4-Week # shares bought: 35,000
  • 12-Week # shares bought: 35,000
  • 24-Week # shares bought: 45,000

The average volume for Alphatec Holdings has been 98,300 shares per day over the past 30 days. Alphatec Holdings has a market cap of $135.8 million and is part of the health care sector and health services industry. Shares are down 3.55% year-to-date as of the close of trading on Friday.

Alphatec Holdings, Inc., a medical technology company, focuses on the design, development, manufacturing, and marketing of products for the surgical treatment of spine disorders worldwide. Currently, there is 1 analyst who rates Alphatec Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATEC - FREE

TheStreet Quant Ratings rates Alphatec Holdings as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Alphatec Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins